<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among 1614 children with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) treated with the Nordic Society for Paediatric Haematology and <z:hpo ids='HP_0002664'>Oncology</z:hpo> (NOPHO) ALL-92 protocol, 20 patients developed a second malignant <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (SMN) with a cumulative risk of 1.6% at 12 years from the diagnosis of ALL </plain></SENT>
<SENT sid="1" pm="."><plain>Nine of the 16 <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> had <z:mp ids='MP_0004026'>monosomy</z:mp> 7 (n = 7) or 7q deletions (n = 2) </plain></SENT>
<SENT sid="2" pm="."><plain>In Cox multivariate analysis, longer duration of oral <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi> (<z:chebi fb="1" ids="2208,50667">6MP</z:chebi>)/<z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) maintenance therapy (P = .02; longest for standard-risk patients) and presence of high hyperdiploidy (P = .07) were related to increased risk of SMN </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="35666">Thiopurine</z:chebi> methyltransferase (TPMT) methylates <z:chebi fb="1" ids="2208,50667">6MP</z:chebi> and its metabolites, and thus reduces cellular levels of cytotoxic 6-thioguanine <z:chebi fb="9" ids="36976">nucleotides</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Of 524 patients who had erythrocyte TPMT activity measured, the median TPMT activity in 9 patients developing an SMN was significantly lower than in the 515 that did not develop an SMN (median, 12.1 vs 18.1 IU/mL; P = .02) </plain></SENT>
<SENT sid="5" pm="."><plain>Among 427 TPMT <z:mp ids='MP_0002169'>wild-type</z:mp> patients for whom the <z:chebi fb="1" ids="2208,50667">6MP</z:chebi> dose was registered, those who developed SMN received higher average <z:chebi fb="1" ids="2208,50667">6MP</z:chebi> doses than the remaining patients (69.7 vs 60.4 mg/m2; P = .03) </plain></SENT>
<SENT sid="6" pm="."><plain>This study indicates that the duration and intensity of 6MP/MTX maintenance therapy of <z:e sem="disease" ids="C0023452" disease_type="Neoplastic Process" abbrv="">childhood ALL</z:e> may influence the risk of SMNs in <z:e sem="disease" ids="C0023452" disease_type="Neoplastic Process" abbrv="">childhood ALL</z:e> </plain></SENT>
</text></document>